Trial
NCT03502694
Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of Oral Lumicitabine Regimens in Hospitalized Adult Participants Infected With Human Metapneumovirus
Phase IIWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
Janssen Research & Development, LLC
Collaborators
—
Condition
Metapneumovirus
Intervention
Lumicitabine
Why stopped
sponsor decision
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2018-11-15